159 related articles for article (PubMed ID: 20470276)
1. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis.
Garcia-Fernandez N; Echeverria A; Sanchez-Ibarrola A; Páramo JA; Coma-Canella I
Nephrology (Carlton); 2010 Mar; 15(2):178-83. PubMed ID: 20470276
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
3. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients.
Tiranathanagul K; Eiam-Ong S; Tosukhowong P; Praditpornsilpa K; Tungsanga K
Nephrology (Carlton); 2004 Aug; 9(4):217-22. PubMed ID: 15363053
[TBL] [Abstract][Full Text] [Related]
5. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
6. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo.
Rooyakkers TM; Stroes ES; Kooistra MP; van Faassen EE; Hider RC; Rabelink TJ; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():9-16. PubMed ID: 11886426
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
8. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study.
Leehey DJ; Palubiak DJ; Chebrolu S; Agarwal R
Nephrol Dial Transplant; 2005 Jan; 20(1):135-40. PubMed ID: 15522899
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction.
Jezovnik MK; Poredos P
Int Angiol; 2010 Jun; 29(3):226-31. PubMed ID: 20502419
[TBL] [Abstract][Full Text] [Related]
10. Endothelial injury markers with high-dose intravenous iron therapy in renal failure.
Borawski J; Gozdzikiewicz J; Abramowicz P; Naumnik B; Mysliwiec M
Clin Appl Thromb Hemost; 2004 Oct; 10(4):403-6. PubMed ID: 15497030
[TBL] [Abstract][Full Text] [Related]
11. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy.
Lim PS; Wei YH; Yu YL; Kho B
Nephrol Dial Transplant; 1999 Nov; 14(11):2680-7. PubMed ID: 10534512
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.
Kuo KL; Hung SC; Wei YH; Tarng DC
J Am Soc Nephrol; 2008 Sep; 19(9):1817-26. PubMed ID: 18495964
[TBL] [Abstract][Full Text] [Related]
13. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
14. Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival.
Suvakov S; Jerotic D; Damjanovic T; Milic N; Pekmezovic T; Djukic T; Jelic-Ivanovic Z; Savic Radojevic A; Pljesa-Ercegovac M; Matic M; McClements L; Dimkovic N; Garovic VD; Albright RC; Simic T
Am J Nephrol; 2019; 50(2):115-125. PubMed ID: 31238306
[TBL] [Abstract][Full Text] [Related]
15. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine modulates effect of the iron isomaltoside on peritoneal mesothelial cells.
Misian M; Baum E; Breborowicz A
J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991316
[TBL] [Abstract][Full Text] [Related]
17. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration.
Kamanna VS; Ganji SH; Shelkovnikov S; Norris K; Vaziri ND
Am J Nephrol; 2012; 35(2):114-9. PubMed ID: 22212390
[TBL] [Abstract][Full Text] [Related]
18. Three monocyte-related determinants of atherosclerosis in haemodialysis.
Jacobson SH; Thylén P; Lundahl J
Nephrol Dial Transplant; 2000 Sep; 15(9):1414-9. PubMed ID: 10978400
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
Roberts MA; Huang L; Lee D; MacGinley R; Troster SM; Kent AB; Bansal SS; Macdougall IC; McMahon LP
BMC Nephrol; 2016 Nov; 17(1):177. PubMed ID: 27852236
[TBL] [Abstract][Full Text] [Related]
20. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
Guz G; Glorieux GL; De Smet R; Waterloos MA; Vanholder RC; Dhondt AW
Nephrol Dial Transplant; 2006 Oct; 21(10):2834-40. PubMed ID: 16762960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
